Home Other Building Blocks 2-Pyrimidinamine, 4-(4-fluoro-1-naphthalenyl)-6-(1-methylethyl)-

2-Pyrimidinamine, 4-(4-fluoro-1-naphthalenyl)-6-(1-methylethyl)-

CAS No.:
199864-87-4
Catalog Number:
AG002CEB
Molecular Formula:
C17H16FN3
Molecular Weight:
281.3274
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
1mg
99%(HPLC)powder
In Stock USA
United States
$47
- +
5mg
99%(HPLC)powder
In Stock USA
United States
$103
- +
10mg
99%(HPLC)powder
In Stock USA
United States
$153
- +
25mg
99%(HPLC)powder
In Stock USA
United States
$294
- +
50mg
99%(HPLC)powder
In Stock USA
United States
$553
- +
Product Description
Catalog Number:
AG002CEB
Chemical Name:
2-Pyrimidinamine, 4-(4-fluoro-1-naphthalenyl)-6-(1-methylethyl)-
CAS Number:
199864-87-4
Molecular Formula:
C17H16FN3
Molecular Weight:
281.3274
MDL Number:
MFCD11112196
IUPAC Name:
4-(4-fluoronaphthalen-1-yl)-6-propan-2-ylpyrimidin-2-amine
InChI:
InChI=1S/C17H16FN3/c1-10(2)15-9-16(21-17(19)20-15)13-7-8-14(18)12-6-4-3-5-11(12)13/h3-10H,1-2H3,(H2,19,20,21)
InChI Key:
ZZZQXCUPAJFVBN-UHFFFAOYSA-N
SMILES:
Nc1nc(cc(n1)c1ccc(c2c1cccc2)F)C(C)C
UNII:
0JAU3P8OBM
Properties
Complexity:
349  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
281.133g/mol
Formal Charge:
0
Heavy Atom Count:
21  
Hydrogen Bond Acceptor Count:
4  
Hydrogen Bond Donor Count:
1  
Isotope Atom Count:
0
Molecular Weight:
281.334g/mol
Monoisotopic Mass:
281.133g/mol
Rotatable Bond Count:
2  
Topological Polar Surface Area:
51.8A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
4  
Literature
Title Journal
Role of peripheral and spinal 5-HT2B receptors in formalin-induced nociception. Pharmacology, biochemistry, and behavior 20120701
Implication of 5-HT(2B) receptors in the serotonin syndrome. Neuropharmacology 20110901
Deconstructing antiobesity compound action: requirement of serotonin 5-HT2B receptors for dexfenfluramine anorectic effects. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20110101
The central serotonin 2B receptor: a new pharmacological target to modulate the mesoaccumbens dopaminergic pathway activity. Journal of neurochemistry 20100901
5-HT(2B) receptors modulate visceral hypersensitivity in a stress-sensitive animal model of brain-gut axis dysfunction. Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 20100501
A selective, high affinity 5-HT 2B receptor antagonist inhibits visceral hypersensitivity in rats. Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 20100201
Inhibition of colonic motility and defecation by RS-127445 suggests an involvement of the 5-HT2B receptor in rodent large bowel physiology. British journal of pharmacology 20090901
A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties. Bioorganic & medicinal chemistry letters 20090415
Role of serotonin via 5-HT2B receptors in the reinforcing effects of MDMA in mice. PloS one 20090101
Pharmacological characterization of 5-Hydroxytryptamine-receptor subtypes in circular muscle from the rat stomach. Biological & pharmaceutical bulletin 20070301
Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn-Schmiedeberg's archives of pharmacology 20040801
Characterization of the contractile 5-hydroxytryptamine receptor in the renal artery of the normotensive rat. The Journal of pharmacology and experimental therapeutics 20040401
Pharmacological profile of YM348, a novel, potent and orally active 5-HT2C receptor agonist. European journal of pharmacology 20040101
Regulation of septo-hippocampal activity by 5-hydroxytryptamine(2C) receptors. The Journal of pharmacology and experimental therapeutics 20030801
Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nature medicine 20021001
MT-500 (POZEN). Current opinion in investigational drugs (London, England : 2000) 20010301
RS-127445: a selective, high affinity, orally bioavailable 5-HT2B receptor antagonist. British journal of pharmacology 19990701
Properties